Single stem cell infusion cut fractures 94% in women with advanced osteoporosis, trial finds

Somewhere in the world, a woman over 50 fractures a bone from osteoporosis roughly every three seconds. A small but striking clinical trial, published in the journal Cell in 2026, suggests that a single intravenous infusion of a patient's own re-engineered stem cells could dramatically change those odds — cutting fracture rates by 94% in the two years after treatment.

The trial enrolled just 10 women aged 51 to 72 with advanced osteoporosis, each of whom had already suffered at least one fracture. Across the group, fragility fractures fell from eight per year before treatment to 0.5 per year in the first two years afterward. Over a median follow-up of nearly six years, the rate dropped further still, to 0.11 fractures per patient-year. No participant experienced a serious treatment-related adverse event.

The research was led by Dr. Robert Sackstein, principal author and director of the Translational Glycobiology Program at the Miami Veterans Affairs Medical Center, working alongside experts from the Hospital Clínico Universitario Virgen de la Arrixaca in Murcia, Spain, the University of Murcia, the Instituto Murciano de Investigación Biosanitaria, and academic groups within Spain's Red de Terapias Avanzadas network, according to telecinco.es.

The therapy's central innovation is a biological navigation system that earlier stem cell approaches lacked. When scientists previously tried injecting regular stem cells into the bloodstream to repair bone, the cells had no reliable way to find damaged bone tissue and the results were disappointing. This study solved that problem by chemically remodeling the surface of each patient's own cells before infusion.

Researchers first extracted bone marrow from each participant's hip bone and grew millions of their mesenchymal stem cells — known as autologous bone marrow-derived MSCs, or autoBM-MSCs — in a laboratory. They then placed those cells in a liquid solution containing a specialized enzyme and a sugar donor molecule called GDP-fucose. This process converted the cells' surface into a structure called HCELL, a biological targeting tag that locks onto receptors lining bone marrow blood vessels, guiding the infused cells directly to damaged bone tissue, according to medicalxpress.com.

After the engineered cells cleared safety testing, each patient received her own modified cells through a single IV drip. The results went beyond fracture counts. Bone biopsies taken before treatment and 120 days afterward showed that mean bone tissue area nearly doubled in most participants. Detailed 3D bone scans at two years confirmed real gains in density deep inside the spongy, trabecular bone. Blood markers of bone-building activity rose and stayed elevated for more than six months after just one infusion. Patients also reported a 34% reduction in bone pain and a 30% improvement in physical disability scores by the 24-month mark.

This research changes the therapeutic philosophy applied until now to treat the disease.— Dr. Robert Sackstein, director of the Translational Glycobiology Program, Miami Veterans Affairs Medical Center

The findings also challenge a common assumption in stem cell research: that cells taken from older or sicker patients are too compromised to be effective. According to medicalxpress.com, the results suggest that with the right preparation, stem cells from this population can perform as well as those from younger donors.

Osteoporosis affects an estimated 75 million people across Europe, the United States, and Japan. Menopause-driven estrogen loss makes women disproportionately vulnerable — one in three women over 50 is at risk of an osteoporosis-related fracture, compared with one in five men over 50. Current treatments, including drugs such as bisphosphonates and anabolic agents, can slow bone loss or modestly promote bone growth, but they require lifelong or repeated use and carry side effects including heartburn, swallowing difficulties, and nausea. Those burdens drive between 30% and 35% of patients to stop taking their prescribed medications, creating what researchers describe as a treatment gap. No cure currently exists.

The critical caveat is the trial's size. Ten participants, no control group, and no direct comparison with existing drugs mean these results — however striking — cannot yet be generalized. The study was a Phase 1 trial designed primarily to test safety, not to prove efficacy at scale. Researchers and independent observers agree that larger, randomized, controlled trials are essential before the therapy could move toward routine clinical use.

That next step is already being planned. According to telecinco.es, a larger clinical trial is expected to begin in 2027, studying the therapy in a broader group of women over 50. The researchers intend to follow that with multicenter trials incorporating more hospitals, patients, and countries, eventually involving several hundred participants.

Why it matters — If confirmed in larger trials, a one-time stem cell infusion could replace lifelong drug regimens for millions of women with advanced osteoporosis — a disease that currently has no cure and causes roughly 10 million fractures a year worldwide.

Reported by medicalxpress.com, sciencealert.com, forbes.com, zmescience.com, telecinco.es